BVBen Viggiano

Ben Viggiano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ben Viggiano has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A high-level programming language for generative biology with Proto

    by Aditi T. Merchant, Daniel Guo, Ben Viggiano, Lucas Brennan-Almaraz, Evelyn Hur, Tina Mai, Peter Yin, Samuel H. King, Euan A. Ashley, Brian L. Hie

    Programmable composition of complex systems is a longstanding goal of biological research. Generative modeling has improved the reliability of computational design, but existing methods are highly specialized and are difficult to extend or compose. Here, we introduce Proto, a high-level programming language for generative biology. By composing a small set of abstract primitives into structured programs, Proto encodes generative design campaigns across diverse modalities and scales—spanning DNA, RNA, proteins, ligands, and their interactions. Proto readily incorporates predictive models into generative workflows, which we leveraged to design alternatively spliced introns with experimental validation in human cell lines. Proto is natively multi-objective, enabling the design of promoter-repressor pairs with leading experimental success rates for synthetic protein-DNA design. Alongside AI agents, Proto enables the specification of complex pathways and regulatory logic through natural language instructions. We openly release Proto, including software infrastructure and user interfaces, to enable widespread access to generative biological programming.


  • Top Cited Papers
    Open Access

    Genome modelling and design across all domains of life with Evo 2

    by Garyk Brixi, Matthew G. Durrant, Jerome Ku, Mohsen Naghipourfar, Michael Poli, Gwanggyu Sun, Greg Brockman, Daniel Chang, Alison Fanton, Gabriel A. Gonzalez, et al.

    All of life encodes information with DNA. Although tools for genome sequencing, synthesis and editing have transformed biological research, we still lack sufficient understanding of the immense complexity encoded by genomes to predict the effects of many classes of genomic changes or to intelligently compose new biological systems. Artificial intelligence models that learn information from genomic sequences across diverse organisms have increasingly advanced prediction and design capabilities1,2. Here we introduce Evo 2, a biological foundation model trained on 9 trillion DNA base pairs from a highly curated genomic atlas spanning all domains of life to have a 1 million token context window with single-nucleotide resolution. Evo 2 learns to accurately predict the functional impacts of genetic variation—from noncoding pathogenic mutations to clinically significant BRCA1 variants—without task-specific fine-tuning. Mechanistic interpretability analyses reveal that Evo 2 learns representations associated with biological features, including exon–intron boundaries, transcription factor binding sites, protein structural elements and prophage genomic regions. The generative abilities of Evo 2 produce mitochondrial, prokaryotic and eukaryotic sequences at genome scale with greater naturalness and coherence than previous methods. Evo 2 also generates experimentally validated chromatin accessibility patterns when guided by predictive models3,4 and inference-time search. We have made Evo 2 fully open, including model parameters, training code5, inference code and the OpenGenome2 dataset, to accelerate the exploration and design of biological complexity.


  • Open Access

    Generative steering to adapt proteins beyond native biological contexts

    by Xiaowei Zhang, Wenhui Sophia Lu, Ben Viggiano, Kevin Reynolds, Sophia Burick, Elena Sotillo, Haoyu Dai, Geonhu Lee, Zixuan Liu, Nuoya Yang, et al.

    Proteins evolved for native biological contexts often fail when deployed in new cellular environments or therapeutic settings. We present ProVADA, a test-time framework that steers a pretrained protein generator toward externally defined properties while preserving functional constraints. Its Mixture-Adaptation Directed Annealing sampler combines coordinated mutations, population selection, and annealing to navigate rugged objective landscapes. Experimentally, ProVADA converted secreted human renin into an active, drug-inhibitable cytosolic protease and extensively deimmunized two murine single-chain antibody fragments to reduce HLA visibility while retaining antigen recognition. ESCAPE-seq measurements confirmed substantial depletion of HLA-I binder peptides across alleles. Deimmunized FMC63 variants retained CAR-T-cell killing and showed fewer binders than a tested humanized comparator. Together, these results demonstrate that broad sequence redesign can adapt functional proteins to non-native biological contexts.


  • Open Access

    Scalable Approach to Consumer Wearable Postmarket Surveillance: Development and Validation Study

    by Richard M Yoo, Ben T Viggiano, Krishna N Pundi, Jason A Fries, Aydin Zahedivash, Tanya Podchiyska, Natasha Din, Nigam H Shah

    Background: With the capability to render prediagnoses, consumer wearables have the potential to affect subsequent diagnoses and the level of care in the health care delivery setting. Despite this, postmarket surveillance of consumer wearables has been hindered by the lack of codified terms in electronic health records (EHRs) to capture wearable use. Objective: We sought to develop a weak supervision–based approach to demonstrate the feasibility and efficacy of EHR-based postmarket surveillance on consumer wearables that render atrial fibrillation (AF) prediagnoses. Methods: We applied data programming, where labeling heuristics are expressed as code-based labeling functions, to detect incidents of AF prediagnoses. A labeler model was then derived from the predictions of the labeling functions using the Snorkel framework. The labeler model was applied to clinical notes to probabilistically label them, and the labeled notes were then used as a training set to fine-tune a classifier called Clinical-Longformer. The resulting classifier identified patients with an AF prediagnosis. A retrospective cohort study was conducted, where the baseline characteristics and subsequent care patterns of patients identified by the classifier were compared against those who did not receive a prediagnosis. Results: The labeler model derived from the labeling functions showed high accuracy (0.92; F1-score=0.77) on the training set. The classifier trained on the probabilistically labeled notes accurately identified patients with an AF prediagnosis (0.95; F1-score=0.83). The cohort study conducted using the constructed system carried enough statistical power to verify the key findings of the Apple Heart Study, which enrolled a much larger number of participants, where patients who received a prediagnosis tended to be older, male, and White with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, stroke, vascular disease, age 65-74 years, sex category) scores (P<.001). We also made a novel discovery that patients with a prediagnosis were more likely to use anticoagulants (525/1037, 50.63% vs 5936/16,560, 35.85%) and have an eventual AF diagnosis (305/1037, 29.41% vs 262/16,560, 1.58%). At the index diagnosis, the existence of a prediagnosis did not distinguish patients based on clinical characteristics, but did correlate with anticoagulant prescription (P=.004 for apixaban and P=.01 for rivaroxaban). Conclusions: Our work establishes the feasibility and efficacy of an EHR-based surveillance system for consumer wearables that render AF prediagnoses. Further work is necessary to generalize these findings for patient populations at other sites.